The FDA Hasn't Approved a New SPF Ingredient Since the Clinton Administration - Until Now

The FDA approved bemotrizinol (BEMT) as a sunscreen active in June 2026. Products can start hitting shelves as early as August 9, 2026. BTW, the rest of the world has been using BEMT since 1999.

Twenty-seven years late? I mean, seriously, FDA, WTF???

Let that sink in. While Europe, Asia, and Australia have had nearly three decades of real-world use of this ingredient (billions of applications, zero safety crises), American consumers have been locked out of it entirely because the U.S. regulatory system classifies sunscreen as a drug and treats it accordingly. This isn’t a breakthrough. It’s a 27-year-overdue correction, and it says a lot about how badly the system has failed us.

---

The Rest of the World Has Used BEMT for 27 Years

Here’s the part that should genuinely annoy you: bemotrizinol isn’t new. It’s been used safely in sunscreens in Europe, Asia, and Australia since 1999. While American consumers were stuck with the same limited selection of SPF actives from a previous century, people across most of the developed world have had nearly three decades of use of this ingredient. Billions of applications. No mass recalls. No safety crises. Just better sun protection than what Americans had access to.

And bemotrizinol isn’t the only one. Several other highly effective UV filters with equally long safety records in global markets have been waiting for the FDA’s review and approval, in some cases for well over a decade. This has created real frustration for U.S. sunscreen formulators trying to create the most effective protection against the UV radiation that causes skin cancer. Americans deserve better.

---

Why Did It Take So Long?

Here’s the context most people don’t know: in the U.S., the FDA classifies sunscreen as an over-the-counter drug, not a cosmetic. That means every active ingredient must undergo a drug approval process before it can legally appear in a sunscreen formula. SPF products are subject to the same regulatory framework that governs pain relievers and cold remedies. In most of the rest of the world, sunscreen is regulated as a cosmetic, which moves considerably faster. So while European and Asian regulators were greenlighting new, more effective UV filters with relative efficiency, the U.S. was running them through a pharmaceutical gauntlet. Same ingredients. Extremely different timelines.

---

What Bemotrizinol Actually Does

This is the part that makes the 27-year wait genuinely frustrating: bemotrizinol is an impressively effective filter.

It delivers outstanding broad-spectrum UVA and UVB protection, which matters because most consumers fixate on SPF numbers (a UVB measure) while UVA radiation, the kind that penetrates deeper and is responsible for both premature aging and skin cancer risk, often gets less attention. Bemotrizinol addresses both. It’s also highly photostable, meaning it doesn’t break down in sunlight the way some older filters do, which has historically been one of the bigger limitations of U.S.-approved actives.

It is approved for adults and children as young as 6 months, and can be used by formulators at concentrations up to 6%. In practical terms, it gives formulators greater flexibility to create lighter, more elegant textures. One of the longstanding complaints about U.S. sunscreen formulas is that they tend to feel heavy and less cosmetically refined than their European counterparts. That gap exists, in large part, because American formulators have been working with effective, yet antiquated ingredients.

---

What Comes Next

Bemotrizinol is the first ingredient to be approved through a new streamlined FDA approval pathway created by the CARES Act. There are other UV filters the rest of the world has been using for years that are still sitting in the FDA queue. If this opens the door for those, too, great. If bemotrizinol turns out to be the exception rather than the new normal, we’ll be having this exact conversation again in a decade or so.

Either way, expect to see BEMT in new product launches before the end of 2026. Your sunscreen is about to get a long-overdue upgrade.

---

#MyTwoCents

Let’s be clear about what the bemotrizinol approval actually is: it’s not a triumph. It’s a correction. The U.S. sunscreen regulatory framework has been an embarrassment relative to global standards for a very long time. Formulators in the EU, Japan, and Australia have spent decades developing more protective, more cosmetically elegant products, while American brands have worked around a regulatory system stuck in the 20th century.

We’re FINALLY catching up. But let’s not throw a party and give out gold stars, because we have a long way to go.

The real story here is what it costs us to be this far behind: the best modern protection against skin cancer. American consumers deserve the same level of UV protection available almost everywhere else in the world. One FDA approval doesn’t fix that. But it’s a start.

What do you think? Let’s discuss in the comments.

---

Kevin James Bennett is the publisher of In My Kit®. He is an Emmy Award-winning makeup artist, cosmetic developer, educator, and consumer advocate. Learn more at www.kjbennett.com